BRAINTREE, Mass., and ROSEMONT, IL, Jan. 30 /PRNewswire-FirstCall/ -- Haemonetics Corporation , a global leader in blood collection technology, announced today that it acquired the assets of Information Data Management, Inc. (“IDM”), a leading developer of software for blood collection agencies for about $9 million in cash. IDM’s software applications for blood collection, blood laboratory operations, and services complement Haemonetics’ 5D(TM) suite of software products and services.
Brad Nutter, Haemonetics’ President and CEO, said, “Blood supply chain management can be significantly optimized through strategic use of information technology. Haemonetics’ 5D(TM) division is already recognized as a market leader in providing information technology to the plasma industry. IDM’s blood bank applications will be added to 5D’s existing product portfolio, enabling Haemonetics to deliver an information management infrastructure to support blood collection and processing.”
Tim Coburn, IDM’s President, said, “We are excited about the possibilities and the strength of a 5D and IDM union, backed by Haemonetics’ reputation in the blood industry.”
Blood collection centers have found that information technology can maximize staff productivity, assist with regulatory compliance, optimize donor resource management and provide management tools to continually improve operations. IDM markets software products which meet the unique needs of blood collectors and which aid customers in blood donor recruitment and management, blood component manufacturing, distribution, and laboratory testing.
IDM generates more than $6 million in annual revenues. Its personnel and operations will remain in the Chicago area following the acquisition.
Haemonetics expects no dilution of earnings.
Haemonetics is a global company engaged in the design, manufacture and worldwide marketing of automated blood processing systems. These systems address important medical markets: surgical blood salvage, blood component collection, plasma collection, and blood component safety. To learn more about Haemonetics’ products and markets, visit its web site at http://www.haemonetics.com.
This release contains forward looking statements that involve risks and uncertainties, including technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand, market acceptance, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers’ ordering patterns, the effect of industry consolidation as seen in the plasma market, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The foregoing list should not be construed as exhaustive. The forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements.
CONTACT: Julie Fallon Tel. (781) 356-9517 Alternate Tel. (617) 320-2401 fallon@haemonetics.com
Haemonetics Corporation
CONTACT: Julie Fallon of Haemonetics, +1-781-356-9517, +1-617-320-2401, orfallon@haemonetics.com
Web site: http://www.haemonetics.com/
